

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
18 September 2003 (18.09.2003)

PCT

(10) International Publication Number  
**WO 03/076469 A2**

(51) International Patent Classification<sup>7</sup>: **C07K 16/00**

(21) International Application Number: PCT/IB03/01458

(22) International Filing Date: 11 March 2003 (11.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/363,045 11 March 2002 (11.03.2002) US

(71) Applicants (for all designated States except US): **PHILO-  
GEN S R L** [IT/IT]; La Lizza 7, I-53100 Siena (IT).  
**SCHERING AG** [DE/DE]; Müller Strasse 170, D-13342  
Berlin (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BORSI, Laura**  
[IT/IT]; Laboratory of Cell Biology Istituto Nazionale per  
la Ricerca sul Cancro, Largo Rosanna Benzi 10, I-16132  
Genova (IT). **CARNEMOLLA, Barbara** [IT/IT]; Labo-  
ratory of Cell Biology Istituto Nazionale per la Ricerca sul  
Cancro, Largo Rosanna Benzi 10, I-16132 Genova (IT).  
**BALZA, Enrica** [IT/IT]; Laboratory of Cell Biology Isti-  
tuto Nazionale per la Ricerca sul Cancro, Largo Rosanna  
Benzi 10, I-16132 Genova (IT). **CASTELLANI, Patrizia**  
[IT/IT]; Laboratory of Cell Biology Istituto Nazionale per  
la Ricerca sul Cancro, Largo Rosanna Benzi 10, I-16132  
Genova (IT). **ZARDI, Luciano** [IT/IT]; Laboratory of  
Cell Biology Istituto Nazionale per la Ricerca sul Cancro,

Largo Rosanna Benzi 10, I-16132 Genova (IT). **FRIEBE,  
Matthias** [DE/DE]; Antonienstr.31, D-13403 Berlin (DE).  
**HILGER, Christoph-Stephan** [DE/DE]; Langenauer  
Weg 24, D-13503 Berlin (DE).

(74) Agents: **SUTCLIFFE, Nicholas, R.** et al.; Mewburn El-  
lis, York House, 23 Kingsway, London, Greater London  
WC2B 6HP (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,  
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: SELECTIVE TARGETING OF TUMOR VASCULATURE USING ANTIBODY MOLECULES

(57) Abstract: The present invention relates to selectively targeting tumoral vasculature in vivo using a human recombinant scFv, L19, to the angiogenesis marker ED-B domain of fibronectin. In preferred embodiments, a complete human IgG1 is employed having the variable regions of L19. In other embodiments is employed a mini-immunoglobulin generated by fusing the scFv L19 to the constant CH4 domain of a secretory IgE isoform that naturally contains a cysteine in its COOH terminal and which forms a covalently linked dimer. Different in vivo behaviour of the antibody formats is exploitable for different diagnostic and/or therapeutic purposes, depending on clinical needs and disease. The antibody molecules may be labelled as described.

WO 03/076469 A2